Tricuspid RegUrgitaTion Hamburg Cohort

Launched by UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF · Feb 14, 2021

Keywords

ClinConnect Summary

The Tricuspid Regurgitation Hamburg Cohort (TRUTH) trial is studying a condition called tricuspid regurgitation (TR), which means that the heart's tricuspid valve isn't closing properly, leading to blood leaking backward. This condition is quite common and can be serious, especially for patients with other heart issues. Currently, surgery is the main treatment option, but it can be risky for many patients. The trial aims to monitor patients with significant TR, regardless of what caused it or how they are being treated, to better understand how to predict outcomes and improve treatment options.

To be eligible for this study, participants need to be at least 18 years old and able to provide informed consent. They must have severe TR (meaning the valve leakage is significant). Unfortunately, individuals who cannot understand German well enough to participate or who have physical or psychological challenges that prevent them from cooperating will not be included. Participants in the trial can expect to be closely monitored and contribute valuable information that could help improve future treatments for TR.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to provide written informed consent in accordance with Good Epidemiological Practice and local legislation.
• • Individuals over the age of 18 years.
• • Patients with clinically relevant tricuspid regurgitation (≥ severe TR, at least Grade III of V)
• Exclusion Criteria:
• • Insufficient knowledge of the German language, to understand study documents and interview without translation
• • Physical or psychological incapability to cooperate in the investigation